Trevi Therapeutics Names David Hastings as Chief Financial Officer

Reuters
2025.12.04 12:30
portai
I'm PortAI, I can summarize articles.

Trevi Therapeutics Inc. has appointed David Hastings as Chief Financial Officer, effective January 6, 2026. Hastings has over 25 years of experience in financial leadership within the life sciences and biopharmaceutical sectors, having held CFO positions at Arbutus, Unilife, Incyte, and ArQule.

Trevi Therapeutics Inc. has appointed David Hastings as Chief Financial Officer, effective January 6, 2026. Hastings brings over 25 years of experience in financial leadership roles within the life sciences and biopharmaceutical sectors, including previous CFO positions at Arbutus, Unilife, Incyte, and ArQule. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trevi Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY39008) on December 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer